Can analysts adopt a bullish outlook for SCYNEXIS, Inc. (NASDAQ:SCYX)?

January 21, 2018 - By Vivian Park

 Can analysts adopt a bullish outlook for SCYNEXIS, Inc. (NASDAQ:SCYX)?
Investors sentiment increased to 1.09 in Q3 2017. Its up 0.09, from 1 in 2017Q2. It is positive, as 5 investors sold SCYNEXIS, Inc. shares while 6 reduced holdings. 4 funds opened positions while 8 raised stakes. 8.55 million shares or 7.29% less from 9.22 million shares in 2017Q2 were reported.
Opus Point Prtnrs Management has 0.14% invested in SCYNEXIS, Inc. (NASDAQ:SCYX). Federated Incorporated Pa holds 4.21M shares or 0.03% of its portfolio. Granite Point Cap Mgmt L P holds 0.07% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX) for 141,750 shares. Us Bank & Trust De reported 31,500 shares. Millennium Mngmt stated it has 40,528 shares. The New York-based Asset Mngmt Incorporated has invested 0.11% in SCYNEXIS, Inc. (NASDAQ:SCYX). Susquehanna International Gru Limited Liability Partnership holds 0% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX) for 34,033 shares. Blackrock Inc holds 0% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX) for 99,827 shares. 506,900 were accumulated by Dafna Capital Mgmt Llc. Creative Planning holds 0% of its portfolio in SCYNEXIS, Inc. (NASDAQ:SCYX) for 47,300 shares. Art Advisors Limited Liability Corp owns 56,127 shares or 0.01% of their US portfolio. Vanguard Gp has 0% invested in SCYNEXIS, Inc. (NASDAQ:SCYX). Virtu Financial Limited Liability Com invested in 74,884 shares. Natl Bank Of Ny Mellon Corporation holds 19,455 shares or 0% of its portfolio. Iguana Healthcare Mngmt holds 250,000 shares.

SCYNEXIS, Inc. (NASDAQ:SCYX) Ratings Coverage

Among 7 analysts covering Scynexis Inc (NASDAQ:SCYX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Scynexis Inc had 13 analyst reports since August 20, 2015 according to SRatingsIntel. Needham maintained the stock with “Hold” rating in Wednesday, August 9 report. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, August 16 report. Brean Capital initiated the shares of SCYX in report on Monday, March 28 with “Buy” rating. H.C. Wainwright initiated SCYNEXIS, Inc. (NASDAQ:SCYX) rating on Thursday, October 20. H.C. Wainwright has “Buy” rating and $14 target. WBB Securities initiated SCYNEXIS, Inc. (NASDAQ:SCYX) rating on Tuesday, December 29. WBB Securities has “Strong Buy” rating and $8.0 target. Brean Capital initiated SCYNEXIS, Inc. (NASDAQ:SCYX) rating on Monday, October 3. Brean Capital has “Buy” rating and $16 target. The stock of SCYNEXIS, Inc. (NASDAQ:SCYX) has “Outperform” rating given on Monday, November 16 by RBC Capital Markets. The stock has “Buy” rating by Needham on Thursday, August 20. WBB Securities upgraded SCYNEXIS, Inc. (NASDAQ:SCYX) on Tuesday, August 9 to “Buy” rating. On Wednesday, August 17 the stock rating was initiated by Guggenheim with “Buy”. Below is a list of SCYNEXIS, Inc. (NASDAQ:SCYX) latest ratings and price target changes.

24/10/2017 Broker: Guggenheim Rating: Buy New Target: $6 Initiates Coverage On
16/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $14.0 Maintain
09/08/2017 Broker: Needham Rating: Hold Maintain
07/08/2017 Broker: Roth Capital Rating: Buy New Target: $8.5000 Maintain

The stock increased 0.54% or $0.01 during the last trading session, reaching $1.85. About 67,778 shares traded. SCYNEXIS, Inc. (NASDAQ:SCYX) has declined 46.67% since January 21, 2017 and is downtrending. It has underperformed by 63.37% the S&P500.

SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The company has market cap of $52.83 million. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. It currently has negative earnings. The firm also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis.

More notable recent SCYNEXIS, Inc. (NASDAQ:SCYX) news were published by: which released: “Scynexis Q2 – Steady As She Goes” on August 21, 2017, also with their article: “Scynexis: Why The Drop? Buy The Drop?” published on March 13, 2017, published: “Scynexis: Is The Delay A Buying Opportunity?” on May 10, 2017. More interesting news about SCYNEXIS, Inc. (NASDAQ:SCYX) were released by: and their article: “SCYNEXIS Appoints Scott Sukenick as General Counsel” published on November 16, 2017 as well as‘s news article titled: “Scynexis: Another Buy Opportunity On The Recent Pullback” with publication date: May 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.